Results: 4

1.
Figure 3

Figure 3. Tau enrichment in the membrane fraction of AD cases. From: Analysis of a membrane enriched proteome from post-mortem human brain tissue in Alzheimer's disease.

An immunoblot (IB) for tau in membrane fraction of individual control and AD cases is shown. Calnexin was used as a loading control. Markers on blots represent molecular weight in kDa.

Laura E. Donovan, et al. Proteomics Clin Appl. ;6(3-4):201-211.
2.
Figure 2

Figure 2. Human brain membrane factions analyzed by LC-MS/MS. From: Analysis of a membrane enriched proteome from post-mortem human brain tissue in Alzheimer's disease.

(A) Representative base peak peptide elution profiles of control and AD sample demonstrate the reproducibility between technical replicate 1 (R1) and replicate 2 (R2). (B) Peptide retention time correlation between R1 and R2 from control and AD samples is provided.

Laura E. Donovan, et al. Proteomics Clin Appl. ;6(3-4):201-211.
3.
Figure 1

Figure 1. Membrane enrichment strategy. From: Analysis of a membrane enriched proteome from post-mortem human brain tissue in Alzheimer's disease.

(A) Flowchart of experimental design to enrich for membrane proteins from human brain tissue. (B) Silver stain showing differential protein banding patterns in each fraction. Immunoblot of PSD-95, a transmembrane domain-containing protein specific to the post synaptic density, demonstrates approximately 2 fold enrichment in the membrane fraction compared with total homogenate. (C) Immunoblots for calnexin, synaptophysin (SYP) and SSBP1 demonstrates that multiple membrane proteins are present in the final membrane fraction.

Laura E. Donovan, et al. Proteomics Clin Appl. ;6(3-4):201-211.
4.
Figure 4

Figure 4. Confirmation of proteomic changes for UCHL1, Munc-18 and A2M. From: Analysis of a membrane enriched proteome from post-mortem human brain tissue in Alzheimer's disease.

(A and B) Immunoblot (IB) analyses of the membrane fraction show that UCHL1 (p = 0.0299) and Munc-18 (p = 0.0012) levels were significantly higher in AD cases. (C) Immunoblot analysis of the membrane fraction reveals A2M levels are elevated in 2 of 5 control cases and no AD cases. This difference is not statistically significant (p = 0.15). All immunoblots are representative of three independent experiments. Calnexin was used as a loading control. Human sample information listed in Table 1. Signal intensity was determined by densitometry and statistical analysis was performed using a two-tailed student’s t-test. An asterisk (*) represents significant difference (p < 0.05)

Laura E. Donovan, et al. Proteomics Clin Appl. ;6(3-4):201-211.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk